{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T02:13:01Z","timestamp":1789956781378,"version":"4.0.1"},"reference-count":45,"publisher":"Public Library of Science (PLoS)","issue":"7","license":[{"start":{"date-parts":[[2014,7,18]],"date-time":"2014-07-18T00:00:00Z","timestamp":1405641600000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"DOI":"10.1371\/journal.pone.0103050","type":"journal-article","created":{"date-parts":[[2014,7,18]],"date-time":"2014-07-18T18:50:41Z","timestamp":1405709441000},"page":"e103050","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":7,"title":["A Meta-Analysis Approach for Characterizing Pan-Cancer Mechanisms of Drug Sensitivity in Cell Lines"],"prefix":"10.1371","volume":"9","author":[{"given":"Kendric","family":"Wang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raunak","family":"Shrestha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander W.","family":"Wyatt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anupama","family":"Reddy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph","family":"Leh\u00e1r","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuzhou","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Lapuk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Colin C.","family":"Collins","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"340","published-online":{"date-parts":[[2014,7,18]]},"reference":[{"key":"ref1","unstructured":"Gillet J, Gottesman MM (2010) Multi-Drug Resistance in Cancer. 596. Available: http:\/\/www.springerlink.com\/index\/10.1007\/978-1-60761-416-6<\/ext-link>. Accessed 25 May 2013."},{"key":"ref2","doi-asserted-by":"crossref","first-page":"S159","DOI":"10.1677\/erc.1.00999","article-title":"Intrinsic and acquired resistance to EGFR inhibitors in human cancer therapy","volume":"12","author":"R Bianco","year":"2005","journal-title":"Endocr Relat Cancer"},{"key":"ref3","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1038\/nrd1984","article-title":"Targeting multidrug resistance in cancer","volume":"5","author":"G Szak\u00e1cs","year":"2006","journal-title":"Nat Rev Drug Discov"},{"key":"ref4","doi-asserted-by":"crossref","first-page":"20932","DOI":"10.1073\/pnas.0710370104","article-title":"MET amplification occurs with or without T790M mutations in EGFR mutant lung tumors with acquired resistance to gefitinib or erlotinib","volume":"104","author":"J Bean","year":"2007","journal-title":"Proc Natl Acad Sci U S A"},{"key":"ref5","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1038\/nrc1951","article-title":"The NCI60 human tumour cell line anticancer drug screen","volume":"6","author":"RH Shoemaker","year":"2006","journal-title":"Nat Rev Cancer"},{"key":"ref6","doi-asserted-by":"crossref","first-page":"1699","DOI":"10.1002\/ijc.21570","article-title":"Gene expression profiling of 30 cancer cell lines predicts resistance towards 11 anticancer drugs at clinically achieved concentrations","volume":"118","author":"B Gy\u00f6rffy","year":"2006","journal-title":"Int J Cancer"},{"key":"ref7","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1038\/nature11005","article-title":"Systematic identification of genomic markers of drug sensitivity in cancer cells","volume":"483","author":"MJ Garnett","year":"2012","journal-title":"Nature"},{"key":"ref8","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1038\/nature11003","article-title":"The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity","volume":"483","author":"J Barretina","year":"2012","journal-title":"Nature"},{"key":"ref9","doi-asserted-by":"crossref","first-page":"8686","DOI":"10.1158\/1078-0432.CCR-05-1492","article-title":"Epithelial versus mesenchymal phenotype determines in vitro sensitivity and predicts clinical activity of erlotinib in lung cancer patients","volume":"11","author":"RL Yauch","year":"2005","journal-title":"Clin Cancer Res"},{"key":"ref10","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1016\/j.ccr.2006.10.008","article-title":"A collection of breast cancer cell lines for the study of functionally distinct cancer subtypes","volume":"10","author":"RM Neve","year":"2006","journal-title":"Cancer Cell"},{"key":"ref11","doi-asserted-by":"crossref","first-page":"4329","DOI":"10.1200\/JCO.2007.12.3968","article-title":"Tumor mRNA expression profiles predict responses to chemotherapy","volume":"25","author":"JD Minna","year":"2007","journal-title":"J Clin Oncol"},{"key":"ref12","doi-asserted-by":"crossref","first-page":"2264","DOI":"10.1158\/0008-5472.CAN-09-1577","article-title":"Transcriptional pathway signatures predict MEK addiction and response to selumetinib (AZD6244)","volume":"70","author":"JR Dry","year":"2010","journal-title":"Cancer Res"},{"key":"ref13","doi-asserted-by":"crossref","first-page":"4245","DOI":"10.1073\/pnas.1208949110","article-title":"Pattern discovery and cancer gene identification in integrated cancer genomic data","volume":"110","author":"Q Mo","year":"2013","journal-title":"Proc Natl Acad Sci U S A"},{"key":"ref14","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1016\/j.cell.2011.02.013","article-title":"Hallmarks of cancer: the next generation","volume":"144","author":"D Hanahan","year":"2011","journal-title":"Cell"},{"key":"ref15","doi-asserted-by":"crossref","first-page":"2650","DOI":"10.1038\/srep02650","article-title":"Comprehensive identification of mutational cancer driver genes across 12 tumor types","volume":"3","author":"D Tamborero","year":"2013","journal-title":"Sci Rep"},{"key":"ref16","doi-asserted-by":"crossref","first-page":"9309","DOI":"10.1073\/pnas.0401994101","article-title":"Large-scale meta-analysis of cancer microarray data identifies common transcriptional profiles of neoplastic transformation and progression","volume":"101","author":"DR Rhodes","year":"2004","journal-title":"Proc Natl Acad Sci U S A"},{"key":"ref17","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1593\/neo.07112","article-title":"Oncomine 3.0: Genes, Pathways, and Networks in a Collection of 18,000 Cancer Gene Expression Profiles","volume":"9","author":"DR Rhodes","year":"2007","journal-title":"Neoplasia"},{"key":"ref18","first-page":"1503","article-title":"Microarray analysis identifies a death-from- cancer signature predicting therapy failure in patients with multiple types of cancer","volume":"115","author":"V Glinsky G","year":"2005"},{"key":"ref19","doi-asserted-by":"crossref","first-page":"3867","DOI":"10.1214\/09-AOS697","article-title":"Karl Pearson's meta-analysis revisited","volume":"37","author":"AB Owen","year":"2009","journal-title":"Ann Stat"},{"key":"ref20","doi-asserted-by":"crossref","first-page":"3785","DOI":"10.1093\/nar\/gkr1265","article-title":"Comprehensive literature review and statistical considerations for microarray meta-analysis","volume":"40","author":"GC Tseng","year":"2012","journal-title":"Nucleic Acids Res"},{"key":"ref21","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1038\/nrc1977","article-title":"Topoisomerase I inhibitors: camptothecins and beyond","volume":"6","author":"Y Pommier","year":"2006","journal-title":"Nat Rev Cancer"},{"key":"ref22","first-page":"2","article-title":"Putative DNA\/RNA helicase Schlafen-11 (SLFN11) sensitizes cancer cells to DNA-damaging agents","volume":"11","author":"G Zoppoli","year":"2012","journal-title":"Proc"},{"key":"ref23","doi-asserted-by":"crossref","first-page":"864","DOI":"10.1158\/1535-7163.MCT-08-0695","article-title":"Chromatin-associated proteins HMGB1\/2 and PDIA3 trigger cellular response to chemotherapy-induced DNA damage","volume":"8","author":"NF Krynetskaia","year":"2009","journal-title":"Mol Cancer Ther"},{"key":"ref24","doi-asserted-by":"crossref","first-page":"e359","DOI":"10.1038\/cddis.2012.76","article-title":"BCLAF1 is a radiation-induced H2AX-interacting partner involved in \u03b3H2AX-mediated regulation of apoptosis and DNA repair","volume":"3","author":"YY Lee","year":"2012","journal-title":"Cell Death Dis"},{"key":"ref25","doi-asserted-by":"crossref","first-page":"3262","DOI":"10.4161\/cc.8.20.9690","article-title":"Chromosomal instability: a composite phenotype that influences sensitivity to chemotherapy","volume":"8","author":"SE McClelland","year":"2009","journal-title":"Cell Cycle"},{"key":"ref26","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1016\/j.ccr.2012.05.015","article-title":"A distinct replication fork protection pathway connects Fanconi anemia tumor suppressors to RAD51-BRCA1\/2","volume":"22","author":"K Schlacher","year":"2012","journal-title":"Cancer Cell"},{"key":"ref27","doi-asserted-by":"crossref","first-page":"229ra42","DOI":"10.1126\/scitranslmed.3008291","article-title":"DNA Repair Pathway Gene Expression Score Correlates with Repair Proficiency and Tumor Sensitivity to Chemotherapy","volume":"6","author":"SP Pitroda","year":"2014","journal-title":"Sci Transl Med"},{"key":"ref28","doi-asserted-by":"crossref","first-page":"2021","DOI":"10.1021\/mp200329f","article-title":"Histone deacetylase inhibitors: emerging mechanisms of resistance","volume":"8","author":"RW Robey","year":"2011","journal-title":"Mol Pharm"},{"key":"ref29","doi-asserted-by":"crossref","first-page":"E592","DOI":"10.1152\/ajpendo.00228.2009","article-title":"Frontiers: PED\/PEA-15, a multifunctional protein controlling cell survival and glucose metabolism","volume":"297","author":"F Fiory","year":"2009","journal-title":"Am J Physiol Endocrinol Metab"},{"key":"ref30","doi-asserted-by":"crossref","first-page":"3015","DOI":"10.1158\/1078-0432.CCR-11-3225","article-title":"Molecular pathways: interferon\/stat1 pathway: role in the tumor resistance to genotoxic stress and aggressive growth","volume":"18","author":"NN Khodarev","year":"2012","journal-title":"Clin Cancer Res"},{"key":"ref31","doi-asserted-by":"crossref","first-page":"18490","DOI":"10.1073\/pnas.0809242105","article-title":"An interferon-related gene signature for DNA damage resistance is a predictive marker for chemotherapy and radiation for breast cancer","volume":"105","author":"RR Weichselbaum","year":"2008","journal-title":"Proc Natl Acad Sci U S A"},{"key":"ref32","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1038\/nrc2521","article-title":"Derailed endocytosis: an emerging feature of cancer","volume":"8","author":"Y Mosesson","year":"2008","journal-title":"Nat Rev Cancer"},{"key":"ref33","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s10549-011-1689-6","article-title":"Glucocorticoid receptor and breast cancer","volume":"130","author":"M Vilasco","year":"2011","journal-title":"Breast Cancer Res Treat"},{"key":"ref34","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1016\/j.molcel.2005.04.021","article-title":"HDAC6 regulates Hsp90 acetylation and chaperone-dependent activation of glucocorticoid receptor","volume":"18","author":"JJ Kovacs","year":"2005","journal-title":"Mol Cell"},{"key":"ref35","doi-asserted-by":"crossref","first-page":"40364","DOI":"10.1074\/jbc.M302999200","article-title":"Tissue inhibitor of metalloproteinase-1 protects human breast epithelial cells against intrinsic apoptotic cell death via the focal adhesion kinase\/phosphatidylinositol 3-kinase and MAPK signaling pathway","volume":"278","author":"X-W Liu","year":"2003","journal-title":"J Biol Chem"},{"key":"ref36","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1038\/nrc2780","article-title":"Fibroblast growth factor signalling: from development to cancer","volume":"10","author":"N Turner","year":"2010","journal-title":"Nat Rev Cancer"},{"key":"ref37","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1517\/14728210903282760","article-title":"Emerging MEK inhibitors","volume":"15","author":"a McCubrey J","year":"2010","journal-title":"Expert Opin Emerg Drugs"},{"key":"ref38","first-page":"1068","article-title":"Ras\/Raf\/MEK\/ERK PI3K\/PTEN\/Akt\/mTOR Cascade Inhibitors: How Mutations Can Result in Therapy Resistance and How to Overcome Resistance Abstract","volume":"3","author":"JA Mccubrey","year":"2012"},{"key":"ref39","doi-asserted-by":"crossref","first-page":"3651","DOI":"10.1158\/1078-0432.CCR-08-0333","article-title":"Advances in the development of cancer therapeutics directed against the RAS-mitogen-activated protein kinase pathway","volume":"14","author":"JS Sebolt-Leopold","year":"2008","journal-title":"Clin Cancer Res"},{"key":"ref40","doi-asserted-by":"crossref","first-page":"5962","DOI":"10.1158\/1078-0432.CCR-08-0651","article-title":"On Trk\u2014the TrkB signal transduction pathway is an increasingly important target in cancer biology","volume":"15","author":"CJ Thiele","year":"2009","journal-title":"Clin Cancer Res"},{"key":"ref41","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1016\/j.yexcr.2009.09.028","article-title":"M-Ras is activated by bone morphogenetic protein-2 and participates in osteoblastic determination, differentiation, and transdifferentiation","volume":"316","author":"H Watanabe-Takano","year":"2010","journal-title":"Exp Cell Res"},{"key":"ref42","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1016\/j.tips.2013.05.002","article-title":"The structure and function of the S1P1 receptor","volume":"34","author":"C O'Sullivan","year":"2013","journal-title":"Trends Pharmacol Sci"},{"key":"ref43","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1016\/j.cell.2012.10.035","article-title":"MED12 controls the response to multiple cancer drugs through regulation of TGF-\u03b2 receptor signaling","volume":"151","author":"S Huang","year":"2012","journal-title":"Cell"},{"key":"ref44","doi-asserted-by":"crossref","first-page":"4286","DOI":"10.1158\/0008-5472.CAN-08-4765","article-title":"PI3K pathway activation mediates resistance to MEK inhibitors in KRAS mutant cancers","volume":"69","author":"S Wee","year":"2009","journal-title":"Cancer Res"},{"key":"ref45","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1038\/nature04304","article-title":"BRAF mutation predicts sensitivity to MEK inhibition","volume":"439","author":"DB Solit","year":"2006","journal-title":"Nature"}],"container-title":["PLoS ONE"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/dx.plos.org\/10.1371\/journal.pone.0103050","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,8,13]],"date-time":"2019-08-13T00:37:27Z","timestamp":1565656647000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0103050"}},"subtitle":[],"editor":[{"given":"Caterina","family":"Cinti","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2014,7,18]]},"references-count":45,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2014,7,18]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0103050","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,7,18]]}}}